$1.12-0.02 (-1.75%)
OPKO Health, Inc.
OPKO Health, Inc. in the Healthcare sector is trading at $1.12. The stock is currently 30% below its 52-week high of $1.60, remaining 14.5% below its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why OPK maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a...
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base.
Despite revenue setbacks, OPKO Health Inc (OPK) shows resilience with strategic advancements and a strong cash position.
OPKO Health (NASDAQ:OPK) reported first-quarter 2026 results and highlighted continued progress across its ModeX Therapeutics pipeline, along with ongoing restructuring in diagnostics and growth in international pharmaceutical operations. ModeX pipeline expands clinical activity and partnerships Ch
OPKO Health (OPK) delivered earnings and revenue surprises of -2.94% and -4.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?